Cosmo Pharmaceuticals (OTC:CMOPF) Trading 4.5% Higher – Should You Buy?

Cosmo Pharmaceuticals (OTC:CMOPF)’s stock price shot up 4.5% on Thursday . The stock traded as high as C$157.81 and last traded at C$157.81. 23 shares changed hands during mid-day trading, a decline of 96% from the average session volume of 593 shares. The stock had previously closed at C$151.00.

Cosmo Pharmaceuticals Stock Performance

The firm’s 50 day moving average is C$138.63 and its 200-day moving average is C$100.53.

Cosmo Pharmaceuticals Company Profile

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide. The company offers Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Lumeblue (methylene blue MMX), a diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; Uceris/Cortiment, an oral tablet formulation which delivers budesonide directly to the lumen of the colon; Aemcolo/Relafalk, a GI antibiotic with MMX® technology and is approved for the treatment of travellers' diarrhoea; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Eleview, a medical device, which enables the safer and faster removal of colonic lesions; and GI Genius, a system that uses artificial intelligence to detect colorectal polyps during colonoscopy.